Showing results (11-20 of 46) with videos related to
Sort By:
Pageof 5
American Journal of Clinical Oncology|February 6, 2004
Phase I study with dose escalation of gemcitabine and cisplatin in combination with ifosfamide (GIP) in patients with non-small-cell lung carcinomaHugues Bourgeois, Isabelle Billiart, Virginie Chabrun, et al.Anticancer Research|October 23, 2009
Pegylated liposomal doxorubicin and carboplatin in late-relapsing ovarian cancer: a GINECO group phase II trialBéatrice Weber, Alain Lortholary, Françoise Mayer, et al.American Journal of Clinical Oncology|August 8, 2006
Gemcitabine, ifosfamide, and cisplatin combination (GIP) in treatment of patients with locally advanced or metastatic nonsmall cell lung cancer: results of a phase II studyDavid Planchard, Hugues Bourgeois, Michèle Adoun, et al.Anticancer Research|August 19, 2007
Exemestane as neoadjuvant hormonotherapy for locally advanced breast cancer: results of a phase II trialMichele Tubiana-Hulin, Veronique Becette, Ivan Bieche, et al.Bulletin Du Cancer|September 16, 2019
[Management of cancer patients with oral therapy at home in Brittany and Pays de la Loire areas: Survey (end of 2016) and cartography]Françoise Grudé, Fanny Marhuenda, Delphine Déniel-Lagadec, et al.JMIR Research Protocols|November 25, 2022
Physical Activity Program for the Survival of Elderly Patients With Lymphoma: Study Protocol for Randomized Phase 3 TrialJonas Dubu, Sébastien Boyas, Virginie Roland, et al.American Journal of Clinical Oncology|June 7, 2006
Phase I-II study of pegylated liposomal doxorubicin combined with weekly paclitaxel as first-line treatment in patients with metastatic breast cancerHugues Bourgeois, Aurélie Ferru, Alain Lortholary, et al.Journal of Medical Internet Research|February 15, 2023
A New Option for Pain Prevention Using a Therapeutic Virtual Reality Solution for Bone Marrow Biopsy (REVEH Trial): Open-Label, Randomized, Multicenter, Phase 3 StudyKatell Le Du, Anne-Lise Septans, Frédéric Maloisel, et al.The Oncologist|July 3, 2021
A Pragmatic Study Evaluating NEPA Versus Aprepitant for Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Moderately Emetogenic ChemotherapyLaurent Zelek, Philippe Debourdeau, Hugues Bourgeois, et al.Breast (Edinburgh, Scotland)|January 12, 2019
Results of PONDx, a prospective multicenter study of the Oncotype DX® breast cancer assay: Real-life utilization and decision impact in French clinical practiceElsa Curtit, Jean-Michel Vannetzel, Jean-Claude Darmon, et al.Pageof 5